Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes Mellitus and Cardiovascular Disease: The Past, Present, and Future (2022)
- Authors:
- Autor USP: SANTOS FILHO, RAUL DIAS DOS - FM
- Unidade: FM
- DOI: 10.1007/s40256-021-00515-4
- Subjects: DIABETES MELLITUS; DOENÇAS CARDIOVASCULARES; FATORES DE RISCO
- Agências de fomento:
- Language: Inglês
- Imprenta:
- Source:
- Título: American journal of cardiovascular drugs
- ISSN: 1175-3277
- Volume/Número/Paginação/Ano: v. 22, n. 4, p. 363-383, 2022
- Status:
- Nenhuma versão em acesso aberto identificada
-
ABNT
FERRARI, Filipe et al. Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes Mellitus and Cardiovascular Disease: The Past, Present, and Future. American journal of cardiovascular drugs, v. 22, n. 4, p. 363-383, 2022Tradução . . Disponível em: https://doi.org/10.1007/s40256-021-00515-4. Acesso em: 17 mar. 2026. -
APA
Ferrari, F., Scheffel, R. S., Martins, V. M., Santos Filho, R. D. dos, & Stein, R. (2022). Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes Mellitus and Cardiovascular Disease: The Past, Present, and Future. American journal of cardiovascular drugs, 22( 4), 363-383. doi:10.1007/s40256-021-00515-4 -
NLM
Ferrari F, Scheffel RS, Martins VM, Santos Filho RD dos, Stein R. Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes Mellitus and Cardiovascular Disease: The Past, Present, and Future [Internet]. American journal of cardiovascular drugs. 2022 ; 22( 4): 363-383.[citado 2026 mar. 17 ] Available from: https://doi.org/10.1007/s40256-021-00515-4 -
Vancouver
Ferrari F, Scheffel RS, Martins VM, Santos Filho RD dos, Stein R. Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes Mellitus and Cardiovascular Disease: The Past, Present, and Future [Internet]. American journal of cardiovascular drugs. 2022 ; 22( 4): 363-383.[citado 2026 mar. 17 ] Available from: https://doi.org/10.1007/s40256-021-00515-4 - Long-term efficacy and safety of mipomersen in patients with familial hypercholesterolaemia: 2-year interim results of an open-label extension
- Familial hypercholesterolaemia: PCSK9 inhibitors are coming [comentário]
- Relation of Hepatic Steatosis to Atherogenic Dyslipidemia
- Cigarette smoking worsens systemic inflammation in persons with metabolic syndrome
- Integrated guidance on the care of familial hypercholesterolaemia from the International FH Foundation
- USPSTF recommendation on screening for lipid disorders in children and adolescents. [Carta]
- Down the rabbit hole: reviewing the evidence for primary prevention of cardiovascular disease in people with obesity
- Relation Between Self-Reported Physical Activity Level, Fitness, and Cardiometabolic Risk
- Global think tank on the clinical considerations and management of lipoprotein(a): The top questions and answers regarding what clinicians need to know
- The Role of Statins in Current Guidelines
Informações sobre a disponibilidade de versões do artigo em acesso aberto coletadas automaticamente via oaDOI API (Unpaywall).
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
